已收盤 07-31 16:00:00 美东时间
+0.032
+11.51%
Valion Bio, Inc. (NASDAQ:VBIO) today announced a major clinical development milestone with the finalization of an clinical trial protocol at Sheba Medical Center, one of the world's leading hospitals, to evaluate Entolimod in cancer patients receiving high doses of irradiation for a rare form of can...
07-21 01:35
On Thursday, Valion Bio (NASDAQ:VBIO) discussed first-quarter financial results...
05-15 05:20
First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based DiagnosticsSAN ANTONIO, May 14, 2026 /PRNewswire/ --
05-15 04:34
Valion Bio (NASDAQ:VBIO) reported quarterly losses of $(2.23) per share. This is a 11.51 percent increase over losses of $(2.52) per share from the same period last year.
05-15 04:08
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Seasoned Biopharmaceutical Attorney with Deep IP, Clinical-Stage, and Nasdaq Public Company Experience Joins Leadership Team SAN ANTONIO, May 4, 2026 /PRNewswire/ -- Valion Bio, Inc. (former...
05-05 04:05
Company Presented Entolimod™ from its TLR5 Platform to the Deputy Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs SAN ANTONIO, April 28, 2026 /PRNewswir...
04-28 20:01
Tivic Health Systems Inc. shares rise 24.10% after hours after announcing a full rebrand to Valion Bio and a strategic pivot toward Entolimod-based immunotherapy development.
04-24 16:17